Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Frankfurt - Delayed Quote EUR

HeraMED Limited (1I4.F)

Compare
0.0095
0.0000
(0.00%)
At close: April 2 at 3:29:02 PM GMT+2
Loading Chart for 1I4.F
  • Previous Close 0.0095
  • Open 0.0095
  • Bid 0.0095 x --
  • Ask 0.0415 x --
  • Day's Range 0.0095 - 0.0095
  • 52 Week Range 0.0070 - 0.0175
  • Volume 0
  • Avg. Volume 0
  • Market Cap (intraday) 9.182M
  • Beta (5Y Monthly) -0.13
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells home based maternity monitoring technology in Australia, United States of America, and Israel. It also provides HeraBEAT, a fetal heart rate monitor use by an expectant mother to monitor their fetus' heartbeat; and HeraCARE, a cloud-based remote maternity care platform. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform; and Broward Health for deployment of its HeraCARE to deliver care outcomes for pregnant mothers. HeraMED Limited was founded in 2011 and is based in Melbourne, Australia.

www.hera-med.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 1I4.F

View More

Performance Overview: 1I4.F

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

1I4.F
5.00%
S&P/ASX 200 [XJO] (^AXJO)
3.66%

1-Year Return

1I4.F
0.00%
S&P/ASX 200 [XJO] (^AXJO)
0.55%

3-Year Return

1I4.F
91.77%
S&P/ASX 200 [XJO] (^AXJO)
4.89%

5-Year Return

1I4.F
89.27%
S&P/ASX 200 [XJO] (^AXJO)
55.11%

Compare To: 1I4.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 1I4.F

View More

Valuation Measures

Annual
As of 4/1/2025
  • Market Cap

    9.09M

  • Enterprise Value

    7.76M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    24.04

  • Price/Book (mrq)

    5.20

  • Enterprise Value/Revenue

    36.91

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -91.62%

  • Return on Equity (ttm)

    -317.64%

  • Revenue (ttm)

    364.33k

  • Net Income Avi to Common (ttm)

    -5.49M

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.17M

  • Total Debt/Equity (mrq)

    2.96%

  • Levered Free Cash Flow (ttm)

    -2.75M

Research Analysis: 1I4.F

View More

Company Insights: 1I4.F

Research Reports: 1I4.F

View More

People Also Watch